MicroT Biotech Raises Over $50 Million as In Vivo CAR-T Enters a Critical Validation Phase
MicroT Biotech has raised over $50 million in Series A and A+ funding to advance GT801, a CD19-targeting in vivo CAR-T candidate. The deal highlights rising institutional confidence in in vivo CAR-T as the field moves from concept to parallel financing, clinical, and industrial validation.








